soul trial oral semaglutide cardiovascular outcomes trial soul results Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes 🧿 Oral semaglutide is the

Local and systemic mechanisms that control the hair follicle stem cell niche

These agents are contraindicated in patients with thyroid NETs (i.e., medullary thyroid carcinoma) or multiple endocrine neoplasia type 2 (MEN2) based on rodent studies suggesting that GLP-1RAs promote tumor growth via activation of GLP-1R on rodent thyroid C-cells (4, 5)

A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways

Under current circumstances, we are not aware of any major delivery issues

Special Notes : The first oral GLP-1 agonist approved for weight loss in Dec 2025

Alongside the extremely promising and award-winning Eriomin is Supresa saffron at 176.5mg, shown in studies to be able to reduce snacking and cravings, and 400mg of Morosil red orange fruit extract backed by benefits of decreased waist size, hip circumference, and body weight